Adicet Bio, Inc. (NASDAQ:ACET) Expected to Earn FY2026 Earnings of ($1.11) Per Share

Adicet Bio, Inc. (NASDAQ:ACET) – Stock analysts at Wedbush issued their FY2026 earnings per share (EPS) estimates for shares of Adicet Bio in a research report issued to clients and investors on Tuesday, September 10th. Wedbush analyst R. Driscoll forecasts that the company will earn ($1.11) per share for the year. Wedbush has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.35) per share. Wedbush also issued estimates for Adicet Bio’s FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($1.03) EPS.

Adicet Bio (NASDAQ:ACET) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.03.

A number of other research analysts also recently weighed in on ACET. HC Wainwright downgraded Adicet Bio from a “buy” rating to a “neutral” rating in a report on Wednesday. StockNews.com cut Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Canaccord Genuity Group lowered their price objective on Adicet Bio from $19.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday.

Adicet Bio Price Performance

Shares of NASDAQ ACET opened at $1.49 on Friday. Adicet Bio has a 1 year low of $1.05 and a 1 year high of $3.77. The stock has a market capitalization of $122.78 million, a P/E ratio of -0.51 and a beta of 1.79. The company’s 50-day moving average is $1.41 and its 200 day moving average is $1.66.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. purchased a new stake in shares of Adicet Bio in the fourth quarter worth $98,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Adicet Bio during the 1st quarter valued at about $28,000. Carlyle Group Inc. increased its stake in Adicet Bio by 39.4% during the 1st quarter. Carlyle Group Inc. now owns 2,948,718 shares of the company’s stock valued at $6,900,000 after purchasing an additional 833,333 shares in the last quarter. Vanguard Group Inc. raised its holdings in Adicet Bio by 85.5% in the first quarter. Vanguard Group Inc. now owns 3,126,578 shares of the company’s stock worth $7,347,000 after buying an additional 1,441,503 shares during the last quarter. Finally, American International Group Inc. lifted its stake in shares of Adicet Bio by 74.2% in the first quarter. American International Group Inc. now owns 26,319 shares of the company’s stock worth $62,000 after buying an additional 11,214 shares in the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.